Biolab Farmacêutica has a patent approved in the USA and is competing in a market worth R$ 1 billion a year
Biolab Farmacêutica has just been granted patents in the United States and Mexico for Onicut gel, its nail strengthener. The topical dermo-cosmetic is now competing in a segment that generates more than R$ 1.1 billion a year in the United States alone.
Cleiton de Castro Marques, Biolab's CEO, explains that this is an important achievement for the company, which focuses on innovation: "We invest 10% of our revenue in research and development to make innovative products available to people in Brazil and other markets. Onicut is the result of this investment".
According to the executive, the product is a highlight of Biolab's portfolio, made up of natural ingredients and has very interesting attractions for large markets, such as the US and Mexico. In addition, other countries are analyzing the patent application.
This is Biolab's second conquest in the international market in 2021. In March, Vonau Flash, the leader in the nausea and vomiting segment, began to be marketed in Colombia, after being launched in Ecuador.